Literature DB >> 31221821

First Strike-Second Strike Strategies in Metastatic Cancer: Lessons from the Evolutionary Dynamics of Extinction.

Robert A Gatenby1,2,3, Jingsong Zhang4, Joel S Brown5,3.   

Abstract

While clinical cancer research has produced many highly effective drugs, the diversity and evolutionary capacity of most cancer populations remain insurmountable barriers to cure. Here, we propose that curative outcomes may, nevertheless, be achieved by sequencing therapies that are individually effective but noncurative. Basic principles for such an approach are derived from the eco-evolutionary dynamics of background extinctions in which a "first strike" reduces the size and heterogeneity of the population. When followed immediately by demographic and ecological "second strikes," the population can be reduced below some minimum threshold, leading inevitably to extinction. This strategy bears strong similarity to the empirically-derived curative therapy in childhood acute lymphocytic leukemia. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31221821      PMCID: PMC6606376          DOI: 10.1158/0008-5472.CAN-19-0807

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Extinction: bad genes or bad luck?

Authors:  D Raup
Journal:  New Sci       Date:  1991-09-14       Impact factor: 0.319

Review 2.  Can oncology recapitulate paleontology? Lessons from species extinctions.

Authors:  Viola Walther; Crispin T Hiley; Darryl Shibata; Charles Swanton; Paul E Turner; Carlo C Maley
Journal:  Nat Rev Clin Oncol       Date:  2015-02-17       Impact factor: 66.675

3.  Aggregation Effects and Population-Based Dynamics as a Source of Therapy Resistance in Cancer.

Authors:  Joel S Brown; Jessica J Cunningham; Robert A Gatenby
Journal:  IEEE Trans Biomed Eng       Date:  2016-11-01       Impact factor: 4.538

Review 4.  Evolution of cooperation among tumor cells.

Authors:  Robert Axelrod; David E Axelrod; Kenneth J Pienta
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-28       Impact factor: 11.205

5.  Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

Authors:  Nicholas D James; Johann S de Bono; Melissa R Spears; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Alastair W S Ritchie; Claire L Amos; Clare Gilson; Rob J Jones; David Matheson; Robin Millman; Gerhardt Attard; Simon Chowdhury; William R Cross; Silke Gillessen; Christopher C Parker; J Martin Russell; Dominik R Berthold; Chris Brawley; Fawzi Adab; San Aung; Alison J Birtle; Jo Bowen; Susannah Brock; Prabir Chakraborti; Catherine Ferguson; Joanna Gale; Emma Gray; Mohan Hingorani; Peter J Hoskin; Jason F Lester; Zafar I Malik; Fiona McKinna; Neil McPhail; Julian Money-Kyrle; Joe O'Sullivan; Omi Parikh; Andrew Protheroe; Angus Robinson; Narayanan N Srihari; Carys Thomas; John Wagstaff; James Wylie; Anjali Zarkar; Mahesh K B Parmar; Matthew R Sydes
Journal:  N Engl J Med       Date:  2017-06-03       Impact factor: 91.245

Review 6.  Turning ecology and evolution against cancer.

Authors:  Kirill S Korolev; Joao B Xavier; Jeff Gore
Journal:  Nat Rev Cancer       Date:  2014-04-17       Impact factor: 60.716

7.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

Authors:  Christopher J Sweeney; Yu-Hui Chen; Michael Carducci; Glenn Liu; David F Jarrard; Mario Eisenberger; Yu-Ning Wong; Noah Hahn; Manish Kohli; Matthew M Cooney; Robert Dreicer; Nicholas J Vogelzang; Joel Picus; Daniel Shevrin; Maha Hussain; Jorge A Garcia; Robert S DiPaola
Journal:  N Engl J Med       Date:  2015-08-05       Impact factor: 91.245

8.  Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma.

Authors:  O A Armas; A G Aprikian; J Melamed; C Cordon-Cardo; D W Cohen; R Erlandson; W R Fair; V E Reuter
Journal:  Am J Surg Pathol       Date:  1994-10       Impact factor: 6.394

9.  Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer.

Authors:  Jingsong Zhang; Jessica J Cunningham; Joel S Brown; Robert A Gatenby
Journal:  Nat Commun       Date:  2017-11-28       Impact factor: 14.919

10.  Outcome for children with metastatic solid tumors over the last four decades.

Authors:  Stephanie M Perkins; Eric T Shinohara; Todd DeWees; Haydar Frangoul
Journal:  PLoS One       Date:  2014-07-08       Impact factor: 3.240

  10 in total
  11 in total

Review 1.  Tumour immunotherapy: lessons from predator-prey theory.

Authors:  Phineas T Hamilton; Bradley R Anholt; Brad H Nelson
Journal:  Nat Rev Immunol       Date:  2022-05-05       Impact factor: 53.106

Review 2.  Integrating evolutionary dynamics into cancer therapy.

Authors:  Robert A Gatenby; Joel S Brown
Journal:  Nat Rev Clin Oncol       Date:  2020-07-22       Impact factor: 66.675

Review 3.  Convergent Evolution, Evolving Evolvability, and the Origins of Lethal Cancer.

Authors:  Kenneth J Pienta; Emma U Hammarlund; Robert Axelrod; Sarah R Amend; Joel S Brown
Journal:  Mol Cancer Res       Date:  2020-03-31       Impact factor: 5.852

4.  Optimal control to reach eco-evolutionary stability in metastatic castrate-resistant prostate cancer.

Authors:  Jessica Cunningham; Frank Thuijsman; Ralf Peeters; Yannick Viossat; Joel Brown; Robert Gatenby; Kateřina Staňková
Journal:  PLoS One       Date:  2020-12-08       Impact factor: 3.240

5.  Cancer Community Ecology.

Authors:  Burt P Kotler; Joel S Brown
Journal:  Cancer Control       Date:  2020 Jan-Dec       Impact factor: 3.302

Review 6.  Novel evolutionary dynamics of small populations in breast cancer adjuvant and neoadjuvant therapy.

Authors:  Yael Artzy-Randrup; Tamir Epstein; Joel S Brown; Ricardo L B Costa; Brian J Czerniecki; Robert A Gatenby
Journal:  NPJ Breast Cancer       Date:  2021-03-11

7.  An evolutionary framework for treating pediatric sarcomas.

Authors:  Damon R Reed; Jonathan Metts; Mariyah Pressley; Brooke L Fridley; Masanori Hayashi; Michael S Isakoff; David M Loeb; Rikesh Makanji; Ryan D Roberts; Matteo Trucco; Lars M Wagner; Mark G Alexandrow; Robert A Gatenby; Joel S Brown
Journal:  Cancer       Date:  2020-03-16       Impact factor: 6.860

8.  Poly-aneuploid cancer cells promote evolvability, generating lethal cancer.

Authors:  Kenneth J Pienta; Emma U Hammarlund; Robert Axelrod; Joel S Brown; Sarah R Amend
Journal:  Evol Appl       Date:  2020-02-22       Impact factor: 5.183

9.  Insights From the Ecology of Information to Cancer Control.

Authors:  Christopher J Whelan; Stanislav S Avdieiev; Robert A Gatenby
Journal:  Cancer Control       Date:  2020 Jul-Aug       Impact factor: 3.302

Review 10.  Senescence-Induced Chemoresistance in Triple Negative Breast Cancer and Evolution-Based Treatment Strategies.

Authors:  Anindita Chakrabarty; Shayantani Chakraborty; Ranjini Bhattacharya; Goutam Chowdhury
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.